Drug Patent, Regulatory Exclusivity, and other protection rights (PTA & PTE and SPC) in Pharmaceuticals Development in US and Europe

Understanding eligibility for drug patents and exclusivity is essential for protecting innovations in the competitive pharmaceutical sector. When a pharmaceutical company develops a new drug, a patent protects this invention from unauthorized use, ensuring that the inventor can recoup the research and development costs throughout the product’s lifecycle. This article discusses the various types of protections for pharmaceutical products granted by intellectual property offices and regulatory authorities, highlighting the differences and similarities between the United States and Europe. By demonstrating the patent protections and regulatory exclusivity, the article provides insights into the specific country’s regulations and criteria that must be met to obtain the patent and the exclusivity rights. In the United States, there are Patent Term Adjustment (PTA) and Patent Term Extension (PTE and in Europe, there is the Supplementary Protection Certificate (SPC). This article illustrates these protection rights and compares their main features. Additionally, it presents straightforward scenarios that outline the key elements influencing the determination and calculation of the protection period, as well as the timely launch of products into the market.